July 2020 in “Journal of The American Academy of Dermatology”
This article proposes expanding dermatologic care through barbershops to improve health access and trust among Black men, particularly for conditions like pseudofolliculitis barbae and acne keloidalis nuchae; it reports no new clinical findings.
November 2025 in “Journal of the Dermatology Nurses’ Association”
This text describes the missions and activities of various organizations focused on supporting people with conditions such as allergies, autoimmune diseases, and skin disorders, emphasizing outreach, education, research, and advocacy. Results from specific studies are not provided.
Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.
DUPA and retrograde alopecia may not be solely DHT-based, and a biopsy is crucial for accurate diagnosis and treatment. Treatments mentioned include dutasteride, oral minoxidil, pioglitazone, clobetasol, calcipotriol, ketoconazole, and doxycycline, depending on the specific condition.
PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.
Finasteride may affect neurosteroids, impacting mood and sexual function, with varied user experiences. Some report side effects like depression and sexual dysfunction, while others find it effective for hair retention or prefer alternatives like Dutasteride or topical treatments.
The conversation discusses hair loss treatments, focusing on finasteride, minoxidil, and other options like PRP and ketoconazole. It highlights the importance of asking specific questions during a dermatology visit to determine the cause of hair loss and appropriate treatments.